



PRESS RELEASE I - /02/2018

PANBioRA Kick-off meeting: solution for a cost-and time-effective risk assessment of biomaterials

The EU-funded project PANBioRA - Personalised And/or Generalised Integrated Biomaterial Risk Assessment has kicked off in January 2018. For the next four years, 17 project partners will collaborate to develop a standardized solution for the evaluation of biomaterials.

Biomaterial-based solutions compromise a significant portion of remedies offered by the healthcare system. However, the currently available methodologies are not sufficient for proper risk assessment of all biomaterial applications. PANBioRA aims at providing a set of tools (protocols and instruments) that can standardize the evaluation of new biomaterials. Moreover, this method will allow for pre-implantation, personalized diagnosis for biomaterial-based applications that will ensure better clinical outcomes and minimize the risks related to the use of established and new biomaterials.

From 30 - 31 January the PANBioRA partners celebrated their kick-off meeting in Brussels. The Project Officer from the European Commission attended on the first meeting day. After a presentation of the project's main objectives and tasks by the scientific coordinator Protip Medical, the administrative coordinator Steinbeis 2i GmbH presented guidelines for the overall EU-project management. Following this, each of the 17 consortium members presented their key expertise, contribution to the project and main staff involved. The multidisciplinary nature of the consortium consisting of SMEs, academic and scientific RTD partners, clinics and technology transfer organisations, underlines the complexity of the innovative concept of PANBioRA.

On the second meeting day, next steps and partner contributions for each task were discussed and defined. One of the main challenges of the project will be the integration of the different technologies into one system, making the determination of user requirements for the integrated PANBioRA systems an essential task, which was finalized during the meeting.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 760921 and is conducted under the topic titled "Development of a reliable methodology for better risk management of engineered biomaterials in Advanced Therapy Medicinal Products and/or Medical Devices".

Personalised And/or Generalised Integrated Biomaterial Risk Assessment



For further information please visit www.panbiora.eu or follow PANBioRA on [Facebook](#), [LinkedIn](#) and [Twitter](#).

Project coordinator:

Scientific coordinator:

Protip Medical SAS

Dr. Nihal Engin Vrana | e.vrana@protipmedical.com | +33 388103063

Administrative coordinator:

Steinbeis 2i GmbH

Timo Doll | doll@steinbeis-europa.de | +49 721 93519141

PANBioRA is coordinated by Steinbeis 2i GmbH in cooperation with 16 partners: Protip Medical (Scientific Coordinator), Dolmen Design and Innovation Limited, Biodevice Systems, Protobios, Elvesys SAS, Steinbeis Advanced Risk Technologies Institute doo Kragujevac, Steinbeis Advanced Risk Technologies GmbH, Commissariat A L'Energie Atomique Et Aux Energies Alternatives, Pro-active, Aalto-Korkeakouluosaatio, Turgut Ozal Education SHA, The University of Nottingham, Agencia Estatal Consejo Superior de Investigaciones Científicas, Dublin City University, Institut National de la Santé et de la Recherche Medicale, Centre Hospitalier Universitaire de Liège